Meningitis
Drug research and approvals for meningitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 41 studies of meningitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 2 approved and 3 open orphan designations naming it, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 41
- Trials authorized in Canada: 7
- FDA orphan approvals: 2
- EU medicines: 5
- Clinical Characteristics, Treatment, Diagnostic Findings, and Outcomes of Tuberculous Meningitis in Indonesia, 2022-2025NCT07929519 · Not reported · Ina-Respond · starts Sep 24, 2026
- Group-based Emotional Awareness and Expression Therapy to Support Recovery After Acquired Brain Injury: A Clinical…NCT07852936 · Not applicable · Uppsala University · starts Sep 15, 2026
- Pain Phenotyping of Rheumatic Diseases - An Observational StudyNCT07829497 · Not reported · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · starts Nov 9, 2026
- Hemorrhage Elimination During Lumbar Puncture Using Ultrasound Measurements (HELPUS)NCT07612644 · Not applicable · Vanderbilt University Medical Center · starts May 16, 2026
- Recovery Trajectory for Coma and Disorders of ConsciousnessNCT07614074 · Not reported · University of California, San Francisco · starts Sep 26, 2023
- Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 MonthsNCT07505810 · Phase 3 · Sinovac Biotech Co., Ltd · starts Mar 25, 2026
- Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 MonthsNCT07505823 · Phase 3 · Sinovac Biotech Co., Ltd · starts Mar 22, 2026
- Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 MonthsNCT07505836 · Phase 3 · Sinovac Biotech Co., Ltd · starts Mar 22, 2026
- Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis/Encephalitis Panel Based on Clinical…NCT07432113 · Not applicable · Federal University of Health Science of Porto Alegre · starts Apr 13, 2026
Approved 7
- MeropenemBacterial penicillin-binding protein inhibitor
- AmikacinBacterial 70S ribosome inhibitor
- FlucytosineThymidylate synthase inhibitor
- Penicillin vBacterial penicillin-binding protein inhibitor
- CeftriaxoneBacterial penicillin-binding protein inhibitor
- AmpicillinBacterial penicillin-binding protein inhibitor
- Neisseria meningitidis factor h binding proteinFactor H binding protein vaccine antigen
Phase 3 5
- AspirinCyclooxygenase inhibitor
- RifampinBacterial DNA-directed RNA polymerase inhibitor
- IsoniazidEnoyl-[acyl-carrier-protein] reductase inhibitor
- PyrazinamideFatty acid synthase inhibitor
- MoxifloxacinTopoisomerase IV inhibitor
Phase 2 4
- LinezolidBacterial 70S ribosome inhibitor
- EthambutolArabinosyltransferase A inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- Ceftobiprole medocaril free acidPenicillin-binding protein 1 inhibitor
Phase 1 or earlier 2
- DoripenemBacterial penicillin-binding protein inhibitor
- DaptomycinCell membrane inhibitor
How its trials ended
384 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 116 whose ending is known, 65% met their primary endpoint, 8% missed it and 28% stopped early.
- Completed, result not reported16944%
- Met its primary endpoint7520%
- Status unknown5715%
- Ongoing4211%
- Stopped: other or unclear164%
- Stopped: enrollment or feasibility123%
- Missed its primary endpoint92%
- Stopped: sponsor or business decision41%
| Sep 15, 2022 | "a phase 1/2, multicenter, randomized, active-controlled, observer-blind, age de-escalation study to evaluate the safety, tolerability, and immunogenicity of…Pneumococcal 25-VALENT conjugate vaccine (ivt PCV-25) | Inventprise Inc. | Pending |
| Nov 13, 2020 | A phase IIIb, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of gsk's meningococcal abcwy vaccine when administered in…Combined meningococcal groups a, b, c, w and y vaccine (GSK3536819A) | GSK | Ongoing |
| Aug 20, 2020 | A phase III, randomized, controlled, observer-blind study to domonstrate effectiveness, immunogenicity and safety of gsk's meningococcal group b and combined…GSK3536819A (combined meningococcal groups a, b, c, w and y vaccine) | GSK | Ongoing |
| Jun 14, 2018 | A phase 2b, randomized, controlled, observer-blind, multi-center, non-inferiority immunogenicity and safety study of two formulations of gsk biologicals…Meningococcal (serogroups a, c, w and y) oligosaccharide CRM197 conjugate… | GSK | Ongoing |
| Sep 17, 2015 | A phase 3b, open label, controlled, multi center, extension study to assess the persistence of bactericidal activity at 4 to 7.5 years after two dose primary…Bexsero | Novartis Pharmaceuticals | Ongoing |
| Sep 16, 2015 | Preparedness for and response to meningococcal outbreaks: a pilot study of the immunogenicity, reactogenicity and tolerability of two schedules of a 4cmenb…Bexsero (multicomponent meningococcal b vaccine (recombinant, adsorbed) | Dalhousie University | Pending |
| Jul 31, 2013 | "immunogenicity and safety study of 1 and 2 doses of gsk biologicals' meningococcal vaccine GSK134612 in toddlers, persistance up to 5 years after vaccination…Nimenrix | GSK | Ongoing |
| Apr 1, 1999 | DepoCytIntrathecal treatment of lymphomatous meningitis. | Pacira Pharmaceuticals, Inc. | Approved |
| Aug 11, 1997 | AmBisomeTreatment of disseminated cryptococcosis including meningitis. | Fujisawa USA, Inc. | Approved |
| Jun 21, 2023 | Flucytosine Injection for intravenous InfusionTreatment of cryptococcal meningitis | Cipla Ltd. | Designated |
| Jan 21, 2003 | MafosfamideTreatment of neoplastic meningitis | Baxter Healthcare Corporation | Designated |
| Mar 5, 2001 | BusulfanIntrathecal therapy for neoplastic meningitis | SuperGen, Inc. | Designated |
| Nov 18, 2020 | MenQuadfiMeningococcal group A, C, W-135 and Y conjugate vaccine | Sanofi Winthrop Industrie | EMA ↗ |
| May 24, 2017 | TrumenbaMeningococcal group b vaccine (recombinant, adsorbed) | Pfizer Europe MA EEIG | EMA ↗ |
| Feb 15, 2016 | VaxelisDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed) | MCM Vaccine B.V. | EMA ↗ |
| Jan 13, 2013 | BexseroMeningococcal group B Vaccine (rDNA, component, adsorbed) | GSK Vaccines S.r.l. | EMA ↗ |
| Apr 20, 2012 | NimenrixMeningococcal groups A, C, W-135 and Y conjugate vaccine | Pfizer Europe MA EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA